Overview

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

Status:
Completed

Trial end date:
2014-05-27

Target enrollment:

Participant gender:

Summary

This is a multi-center phase II study assessing whether cabazitaxel could be efficient for treatment of recurrent or metastatic head and neck cancer after failure of cisplatin, cetuximab and taxanes.

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Treatments:

Cetuximab
Cisplatin
Taxane